Therapeutic Effects of W-061 in Murine DSS Colitis
Author Information
Author(s): Sanada Yasuaki, Mizushima Tsunekazu, Kai Yasuyuki, Nishimura Junichi, Hagiya Hiroshi, Kurata Haruto, Mizuno Hirotaka, Uejima Etsuko, Ito Toshinori
Primary Institution: Osaka University, Japan
Hypothesis
The study investigates the effects of a novel sphingosine-1-phosphate receptor agonist W-061 on immune responses in a mouse model of DSS-induced colitis.
Conclusion
W-061 may be a novel therapeutic strategy to ameliorate acute aggravation of inflammatory bowel diseases.
Supporting Evidence
- W-061 treatment improved body weight and colon length in DSS-treated mice.
- Histological analysis showed reduced cellular infiltration in the colon of W-061 treated mice.
- W-061 administration inhibited the migration of Th17 and Th1 cells to the lamina propria.
Takeaway
Researchers tested a new medicine called W-061 on mice with gut inflammation and found it helped them feel better by reducing certain bad immune cells.
Methodology
Mice were treated with DSS to induce colitis, followed by daily administration of W-061, and various immune responses were measured.
Participant Demographics
Male Balb/c mice, aged 6-7 weeks.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website